Tesamorelin
A stabilized GHRH analog approved as Egrifta SV for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy — one of the few approved peptides in the GH axis.
CJC-1295 without DAC (Mod GRF 1-29)
The same GHRH 1-29 modification without the albumin-binding linker — often sold as "Mod GRF 1-29" — producing a shorter-acting GH stimulus closer to native GHRH kinetics.
What each molecule is
Tesamorelin is a GHRH analog — a modified 1-44 fragment — approved specifically for reduction of excess abdominal fat in HIV-associated lipodystrophy. CJC-1295 (Mod GRF 1-29) is a shorter modified GHRH fragment that stalled in early development and never gained an indication anywhere.
Evidence
Tesamorelin has randomized controlled trials in its target population, an approved label, and post-marketing surveillance. CJC-1295 has phase-1 pharmacokinetics, sparse human data, and a development history that ended short of registrational studies.
Why approval matters here
Same receptor, same general mechanism — one compound earned a defined benefit-risk statement for a specific population under supervision; the other remains a mechanism in search of evidence. This pairing shows that mechanism alone predicts nothing about medical value.
Safety
Tesamorelin’s labeled profile includes injection-site reactions and glucose considerations, managed clinically. CJC-1295’s human safety data are minimal, and it is prohibited in sport along with all GH secretagogues.
Practical takeaway
The existence of an approved GHRH analog does not validate the unapproved one — if anything it highlights exactly what the unapproved one is missing.
Frequently Asked Questions
If they work the same way, why did only one get approved?
Because approval requires demonstrated benefit in defined patients with characterized risks — a bar tesamorelin cleared and CJC-1295 never attempted.
Is tesamorelin used off-label?
Off-label use happens under clinician judgment with a real, traceable pharmaceutical product — categorically different from gray-market CJC-1295 of unverifiable identity.
Do both stimulate natural GH release?
Yes — that shared mechanism is exactly why this comparison is instructive rather than favorable to CJC-1295.
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.